The global blood screening market is expected to reach USD 2.80 Billion by 2021 from USD 1.76 Billion in 2016, at a CAGR of 9.7% from 2016 to 2021. The major factors driving the growth of this market are increasing number of blood donations and blood donors, growing affordability and adoption of nucleic acid amplification test (NAT) for blood screening, rising awareness regarding the safety of donated blood, growing demand for donated blood, and increasing prevalence/incidence of infectious diseases.
Browse 97 market data tables and 39 figures spread through 150 pages and in-depth TOC on “Blood Screening Market”
https://www.marketsandmarkets.com/Market-Reports/blood-screening-market-267747042.html
On the basis of technology, the market is segmented into NAT, ELISA, rapid tests, western blot assays, and NGS. The NAT segment is further subsegmented into transcription-mediated amplification (TMA) and real-time PCR. The ELISA segment is further classified based on various platforms and generations. On the basis of platform, the ELISA market is segmented into chemiluminescence immunoassay (CLIA), fluorescence immunoassays (FIA), and colorimetric immunoassay (CI). On the basis of generation, the ELISA market is segmented into first generation ELISA, second generation ELISA, third generation ELISA, and fourth & above generation ELISA.
On the basis of product and service, the blood screening market is segmented into reagents & kits, instruments, and software & services. The reagents & kits segment is further subsegmented into NAT reagents and kits, ELISA reagents and kits, and other reagents and kits. On the basis of purchase mode, the instruments market is segmented into rental purchase and outright purchase.
Download FREE Brochure @ https://www.marketsandmarkets.com/pdfdownload.asp?id=267747042
Based on end user, the blood screening market is segmented into blood banks and hospitals.
Based on region, the market is segmented into North America, Europe, Asia, and RoW.
The major players in the blood screening market are Grifols (Spain), Bio-Rad Laboratories, Inc. (U.S.), Roche Diagnostics (Switzerland), bioMérieux (France), Abbott Laboratories (U.S.), Siemens Healthineers (Germany), Thermo Fisher Scientific, Inc. (U.S.), Beckman Coulter, Inc. (U.S.), Ortho Clinical Diagnostics, Inc. (U.S.), and Becton, Dickinson and Company (U.S).
Hi! I am a robot. I just upvoted you! I found similar content that readers might be interested in:
https://www.marketsandmarkets.com/Market-Reports/blood-screening-market-267747042.html
Downvoting a post can decrease pending rewards and make it less visible. Common reasons:
Submit